ARCHIVES

Revlimid Shows 91 Percent Response in Non-Hodgkin’s

This article is from The Cancer Letter archive.

Vol. 34 No. 7 | July 29, 2011

Download PDF Visit The Full Archive

Related Articles

User Fees Proposed For FDA Oversight Services; Industry Groups Call It “Tax On Innovations”

January 20, 1989

Letters: Alternatives Needs Scrutiny, Investigator Open-Mindedness

December 3, 1993

Six Surgical Oncology Grants To Be Funded

June 8, 1984

Advisors Reaffirm Survival As Standard For full FDA Approval Of Cancer Drugs

June 16, 1999

Propac To Recommend Reclassification Of Five Leukemia/Lymphoma Diagnosis Related Groups

March 21, 1986

Clinical Trials: “Master Protocol” To Rely On Biomarkers In Testing Multiple Lung Cancer Agents

November 15, 2013